Background: The mu-opioid antagonist naltrexone is one of the few approved pharmacotherapies for the treatment of alcohol dependence. Recently, the mu-opioid antagonist and partial kappa agonist nalmefene was approved by the European Medicines Agency for the reduction of alcohol consumption in adult patients with alcohol dependence. To date, no head-to-head studies have compared the efficacy and safety of naltrexone and nalmefene in reducing alcohol consumption.
Methods: An indirect meta-analysis of randomized controlled studies on these 2 medications was conducted. A random effects model was used to measure effects and compare the 2 medications. 4 placebo-controlled studies with nalmefene and 13 with naltrexone were included.
Results: A statistically significant advantage of nalmefene towards naltrexone in the 2 patient-relevant outcome efficacy criteria, quantity and frequency of drinking, was found. Both drugs had a benign safety profile.
Conclusions: This indirect meta-analysis indicates an advantage of nalmefene over naltrexone. Nalmefene is an effective and well-tolerated medication for the reduction of alcohol consumption. Additional data are necessary to demonstrate possible advantages of nalmefene over naltrexone in the treatment of alcohol dependence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0035-1565184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modern pharmacotherapy guidance for treating alcohol use disorders.
Expert Opin Pharmacother
December 2024
Forel Clinic, Addiction Treatment Center, Switzerland.
Introduction: Alcohol use disorder (AUD) is prevalent and recognized as a chronic, relapsing disorder. Even though effective treatment options are available, AUD is strongly undertreated. As adjuvant treatment strategies accompanying psychosocial treatments, pharmacological strategies can increase the efficacy of AUD treatment options.
View Article and Find Full Text PDFPharmacological management of gambling disorder: A systematic review and network meta-analysis.
Compr Psychiatry
February 2025
Department of Psychiatry, Faculty of Medicine, University of Southampton, UK and Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK.
Article Synopsis
- Clinical guidelines for medications treating gambling disorder are unclear, prompting a network meta-analysis to compare their efficacy and tolerability.
- The study reviewed 22 randomized controlled trials, ultimately analyzing 16 with nearly 1,000 participants, focusing on gambling symptom severity and quality of life as efficacy outcomes.
- Nalmefene showed the most promise in reducing gambling severity and improving quality of life, although it and naltrexone had higher dropout rates due to side effects, indicating lower tolerability compared to placebo.
Introduction: Approved treatments for alcohol use disorder by regulatory agencies.
Int Rev Neurobiol
November 2024
Molecular and Behavioral Neuroscience Laboratory, Department of Pharmacology, Universidade Federal de São Paulo (UNIFESP), São Paulo, São Paulo, Brazil. Electronic address:
Alcohol, the most widely consumed substance globally, can lead to severe adverse effects for both users and those around them. Chronic ethanol consumption may lead to alcohol use disorder (AUD), a chronic relapsing condition characterized by compulsive drinking despite negative consequences. AUD is marked by a high relapse rate among individuals attempting abstinence.
View Article and Find Full Text PDFThe Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research.
CNS Drugs
January 2025
School of Population and Global Health, University of Western Australia, Nedlands, WA, 6009, Australia.
Article Synopsis
- - The study reviews the safety concerns of various alcohol pharmacotherapies during pregnancy, as current options for pregnant individuals with alcohol use disorders (AUD) are limited due to unknown teratogenic risks.
- - A total of 105 studies were analyzed, focusing on medications like naltrexone, acamprosate, disulfiram, and topiramate, with findings suggesting that naltrexone might be safer than other options for opioid use disorders, despite being less studied for AUD specifically.
- - The review highlights significant safety concerns, noting disulfiram and topiramate's links to congenital anomalies, while acamprosate showed potential neuroprotective benefits without clear adverse effects, creating a complex picture of risks and benefits
Time Course of Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone.
J Clin Pharmacol
February 2025
Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P., Stamford, CT, USA.
The increase in opioid overdose deaths, particularly involving potent, long-acting synthetic opioids, has led to calls for stronger, longer-acting opioid-overdose-reversal agents. Using an opioid-induced respiratory depression model, we investigated the onset and time course of action of naloxone and a long-acting opioid antagonist, nalmefene, in reversing the effects of an ongoing intravenous fentanyl infusion over a period of up to 100 min. Healthy, moderately experienced opioid users received intramuscular (IM) nalmefene 1 mg, IM naloxone 2 mg, or intranasal (IN) naloxone 4 mg after fentanyl-induced respiratory depression was established based on reduction in respiratory minute volume (MV).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!